Better tracking of immunotherapy side effects study
Part of Cancer clinical trials.
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received or are currently receiving a treatment that includes one or more immunotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers in the blood that might predict side effects from immune checkpoint inhibitor therapy. By identifying these markers, doctors may better manage or prevent side effects for future patients.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study looks at patients who had side effects from cancer immunotherapy (checkpoint inhibitors). The goal is to understand those side effects and whether it is safe to restart immunotherapy after they resolve.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
This study sets up a real-world patient database to follow people starting cancer immunotherapy and record immune-related side effects. You may help doctors better understand who gets these side effects and how they change over time.
This study looks at whether extra monitoring and faster referrals to specialists can help manage side effects from immunotherapy (a treatment that helps your immune system fight cancer). It may make treatment easier to handle.
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.